Therapeutic advancements for glioblastoma have seen minimal progress over the last two decades. Despite promising results in preclinical and early-phase trials, many phase III trials have failed to meet their primary endpoints. In response, a Society for Neuro-Oncology Think Tank convened in November 2020 to identify and prioritize areas for improvement in the conduct of glioblastoma clinical trials.
This review focuses on the challenges related to clinical trial eligibility criteria and trial design in glioblastoma. It provides a comprehensive analysis of the key study design features of adult glioblastoma clinical trials that were listed as "recruiting" or "not yet recruiting" on ClinicalTrials.gov as of February 2021. The findings and recommendations from the Think Tank aim to guide future research efforts towards more effective therapeutic strategies for glioblastoma patients.
